313 related articles for article (PubMed ID: 10933046)
1. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.
Gong MC; Latouche JB; Krause A; Heston WD; Bander NH; Sadelain M
Neoplasia; 1999 Jun; 1(2):123-7. PubMed ID: 10933046
[TBL] [Abstract][Full Text] [Related]
2. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
3. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
4. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
5. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
6. Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Gade TP; Hassen W; Santos E; Gunset G; Saudemont A; Gong MC; Brentjens R; Zhong XS; Stephan M; Stefanski J; Lyddane C; Osborne JR; Buchanan IM; Hall SJ; Heston WD; Rivière I; Larson SM; Koutcher JA; Sadelain M
Cancer Res; 2005 Oct; 65(19):9080-8. PubMed ID: 16204083
[TBL] [Abstract][Full Text] [Related]
7. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
Maher J; Brentjens RJ; Gunset G; Rivière I; Sadelain M
Nat Biotechnol; 2002 Jan; 20(1):70-5. PubMed ID: 11753365
[TBL] [Abstract][Full Text] [Related]
8. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
9. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
10. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
[TBL] [Abstract][Full Text] [Related]
11. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
Lu J; Celis E
Cancer Res; 2002 Oct; 62(20):5807-12. PubMed ID: 12384542
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
Lupold SE; Hicke BJ; Lin Y; Coffey DS
Cancer Res; 2002 Jul; 62(14):4029-33. PubMed ID: 12124337
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
Sugimoto Y; Hirota M; Yoshikawa K; Sumitomo M; Nakamura K; Ueda R; Niwa R; Suzawa T; Yamasaki M; Shitara K; Kato T; Nakamura K
Anticancer Res; 2014 Jan; 34(1):89-97. PubMed ID: 24403448
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells.
Wang K; Gao X; Pang J; Liu X; Cai Y; Zhang Y; Zhou J; Zhan H
Urol Oncol; 2009; 27(1):26-32. PubMed ID: 18367124
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
18. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.
Kobayashi H; Omiya R; Sodey B; Yanai M; Oikawa K; Sato K; Kimura S; Senju S; Nishimura Y; Tateno M; Celis E
Clin Cancer Res; 2003 Nov; 9(14):5386-93. PubMed ID: 14614024
[TBL] [Abstract][Full Text] [Related]
19. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
